Gamma-glutamyl transferase level predicts the development of hypertension in Hong Kong Chinese

Clinica Chimica Acta

Volumn 412, Issue 15-16, 2011, Pages 1326-1331

  Cheung, Bernard M Y ^a   Ong, Kwok Leung ^a   Tso, Annette W K ^a   Cherny, Stacey S ^a,b   Sham, Pak Chung ^a,b   Lam, Tai Hing ^a   Lam, Karen S L ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Glutamyl transaminase; GGT; Hypertension; Liver function test

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIHYPERTENSIVE AGENT; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE; CHINESE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HONG KONG; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ASIAN CONTINENTAL ANCESTRY GROUP; BIOLOGICAL MARKERS; BLOOD PRESSURE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HONG KONG; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS;

EID: 79956298906     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.03.030     Document Type: Article

References (41)

1. Moore J.B. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010, 69:211-220.
2. Hanley A.J., Williams K., Festa A., Wagenknecht L.E., D'Agostino R.B., Haffner S.M. Liver markers and development of the metabolic syndrome: the insulin resistance atherosclerosis study. Diabetes 2005, 54:3140-3147.
3. Mason J.E., Starke R.D., Van Kirk J.E. Gamma-glutamyl transferase: a novel cardiovascular risk biomarker. Prev Cardiol 2010, 13:36-41.
4. Yamada Y., Ishizaki M., Kido T., et al. Alcohol, high blood pressure, and serum gamma-glutamyl transpeptidase level. Hypertension 1991, 18:819-826.
5. Miura K., Nakagawa H., Nakamura H., et al. Serum gamma-glutamyl transferase level in predicting hypertension among male drinkers. J Hum Hypertens 1994, 8:445-449.
6. Kotani K., Shimohiro H., Adachi S., Sakane N. Changes in serum gamma-glutamyl transferase and blood pressure levels in subjects with normal blood pressure and prehypertension. Clin Chim Acta 2008, 389:189-190.
7. Lee D.H., Ha M.H., Kim J.R., Gross M., Jacobs D.R. Gamma-glutamyltransferase, alcohol, and blood pressure. A four year follow-up study. Ann Epidemiol 2002, 12:90-96.
8. Lee D.H., Jacobs D.R., Gross M., et al. Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem 2003, 49:1358-1366.
9. Stranges S., Trevisan M., Dorn J.M., Dmochowski J., Donahue R.P. Body fat distribution, liver enzymes, and risk of hypertension: evidence from the Western New York Study. Hypertension 2005, 46:1186-1193.
10. Cheung B.M., Ong K.L., Cheung R.V., et al. Association between plasma alkaline phosphatase and C-reactive protein in Hong Kong Chinese. Clin Chem Lab Med 2008, 46:523-527.
11. Webber M., Krishnan A., Thomas N.G., Cheung B.M. Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 2005-2006. Clin Chem Lab Med 2010, 48:167-173.
12. Sesso H.D., Buring J.E., Rifai N., Blake G.J., Gaziano J.M., Ridker P.M. C-reactive protein and the risk of developing hypertension. JAMA 2003, 290:2945-2951.
13. Vozarova B., Stefan N., Lindsay R.S., et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002, 51:1889-1895.
14. Sattar N., Scherbakova O., Ford I., et al. Elevated alanine aminotransferase predicts new-onset type 2 diabetes independently of classical risk factors, metabolic syndrome, and C-reactive protein in the west of Scotland coronary prevention study. Diabetes 2004, 53:2855-2860.
15. Ford E.S., Schulze M.B., Bergmann M.M., Thamer C., Joost H.G., Boeing H. Liver enzymes and incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes Care 2008, 31:1138-1143.
16. Sato K.K., Hayashi T., Nakamura Y., et al. Liver enzymes compared with alcohol consumption in predicting the risk of type 2 diabetes: the Kansai Healthcare Study. Diabetes Care 2008, 31:1230-1236.
17. Fraser A., Harris R., Sattar N., Ebrahim S., Davey Smith G., Lawlor D.A. Alanine aminotransferase, gamma-glutamyltransferase, and incident diabetes: the British Women's Heart and Health Study and meta-analysis. Diabetes Care 2009, 32:741-750.
18. Cheung B.M., Wat N.M., Man Y.B., et al. Development of diabetes in Chinese with the metabolic syndrome: a 6-year prospective study. Diabetes Care 2007, 30:1430-1436.
19. Cheung B.M., Wat N.M., Man Y.B., et al. Relationship between the metabolic syndrome and the development of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study-2 (CRISPS2). Am J Hypertens 2008, 21:17-22.
20. Cheung B.M., Wat N.M., Tam S., et al. Components of the metabolic syndrome predictive of its development: a 6-year longitudinal study in Hong Kong Chinese. Clin Endocrinol Oxf 2008, 68:730-737.
21. Cheung B.M., Wat N.M., Tso A.W., et al. Association between raised blood pressure and dysglycemia in Hong Kong Chinese. Diabetes Care 2008, 31:1889-1891.
22. Lam T.H., Liu L.J., Janus E.D., Bourke C., Hedley A.J. The relationship between fibrinogen and other coronary heart disease risk factors in a Chinese population. Atherosclerosis 1999, 143:405-413.
23. Lui M.M., Lam J.C., Mak H.K., et al. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009, 135:950-956.
24. Cui J.S., Hopper J.L., Harrap S.B. Antihypertensive treatments obscure familial contributions to blood pressure variation. Hypertension 2003, 41:207-210.
25. Nilssen O., Førde O.H., Brenn T. The Tromsø Study. Distribution and population determinants of gamma-glutamyltransferase. Am J Epidemiol 1990, 132:318-326.
26. Yamada Y., Ikai E., Tsuritani I., Ishizaki M., Honda R., Ishida M. The relationship between serum gamma-glutamyl transpeptidase levels and hypertension: common in drinkers and nondrinkers. Hypertens Res 1995, 18:295-301.
27. Shankar A., Li J. Association between serum gamma-glutamyltransferase level and prehypertension among US adults. Circ J 2007, 71:1567-1572.
28. Kawamoto R., Kohara K., Tabara Y., Kusunoki T., Otsuka N., Miki T. Association between serum gamma-glutamyl transferase level and prehypertension among community-dwelling men. Tohoku J Exp Med 2008, 216:213-221.
29. Rantala A.O., Lilja M., Kauma H., Savolainen M.J., Reunanen A., Kesäniemi Y.A. Gamma-glutamyl transpeptidase and the metabolic syndrome. J Intern Med 2000, 248:230-238.
30. Onat A., Hergenç G., Karabulut A., et al. Serum gamma glutamyltransferase as a marker of metabolic syndrome and coronary disease likelihood in nondiabetic middle-aged and elderly adults. Prev Med 2006, 43:136-139.
31. Lee D.H., Lim J.S., Yang J.H., Ha M.H., Jacobs D.R. Serum gamma-glutamyltransferase within its normal range predicts a chronic elevation of alanine aminotransferase: a four year follow-up study. Free Radic Res 2005, 39:589-593.
32. Wannamethee G., Ebrahim S., Shaper A.G. Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes. Am J Epidemiol 1995, 142:699-708.
33. Ruttmann E., Brant L.J., Concin H., Diem G., Rapp K. Vorarlberg Health Monitoring and Promotion Program Study Group. Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137.
34. Kazemi-Shirazi L., Endler G., Winkler S., Schickbauer T., Wagner O., Marsik C. Gamma glutamyltransferase and long-term survival: is it just the liver?. Clin Chem 2007, 53:940-946.
35. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:127-133.
36. André P., Balkau B., Vol S., Charles M.A. Gamma-glutamyltransferase activity and development of the metabolic syndrome (International Diabetes Federation Definition) in middle-aged men and women: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort. Diabetes Care 2007, 30:2355-2361. DESIR Study Group.
37. Lee D.H., Ha M.H., Kim J.H., et al. Gamma-glutamyltransferase and diabetes - a 4year follow-up study. Diabetologia 2003, 46:359-364.
38. Perry I.J., Wannamethee S.G., Shaper A.G. Prospective study of serum gamma-glutamyltransferase and risk of NIDDM. Diabetes Care 1998, 21:732-737.
39. Lee D.H., Gross M.D. Cardiovascular Risk Development in Young Adults Study. Association of serum carotenoids and tocopherols with gamma-glutamyltransferase: the Cardiovascular Risk Development in Young Adults (CARDIA) Study. Clin Chem 2004, 50:582-588.
40. Dominici S., Valentini M., Maellaro E., et al. Redox modulation of cell surface protein thiols in U937 lymphoma cells: the role of gamma-glutamyl transpeptidase-dependent H2O2 production and S-thiolation. Free Radic Biol Med 1999, 27:623-635.
41. Kerner A., Avizohar O., Sella R., et al. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome. Arterioscler Thromb Vasc Biol 2005, 25:193-197.